1. Home
  2. TECX vs BSVN Comparison

TECX vs BSVN Comparison

Compare TECX & BSVN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • TECX
  • BSVN
  • Stock Information
  • Founded
  • TECX 2019
  • BSVN 2004
  • Country
  • TECX United States
  • BSVN United States
  • Employees
  • TECX N/A
  • BSVN N/A
  • Industry
  • TECX
  • BSVN Major Banks
  • Sector
  • TECX
  • BSVN Finance
  • Exchange
  • TECX Nasdaq
  • BSVN Nasdaq
  • Market Cap
  • TECX 334.4M
  • BSVN 335.6M
  • IPO Year
  • TECX 2018
  • BSVN 2018
  • Fundamental
  • Price
  • TECX $21.51
  • BSVN $38.62
  • Analyst Decision
  • TECX Buy
  • BSVN Buy
  • Analyst Count
  • TECX 6
  • BSVN 2
  • Target Price
  • TECX $79.20
  • BSVN $51.00
  • AVG Volume (30 Days)
  • TECX 172.8K
  • BSVN 21.2K
  • Earning Date
  • TECX 05-08-2025
  • BSVN 07-10-2025
  • Dividend Yield
  • TECX N/A
  • BSVN 2.46%
  • EPS Growth
  • TECX N/A
  • BSVN 46.15
  • EPS
  • TECX N/A
  • BSVN 4.71
  • Revenue
  • TECX N/A
  • BSVN $96,026,000.00
  • Revenue This Year
  • TECX N/A
  • BSVN N/A
  • Revenue Next Year
  • TECX N/A
  • BSVN $3.53
  • P/E Ratio
  • TECX N/A
  • BSVN $8.20
  • Revenue Growth
  • TECX N/A
  • BSVN 28.97
  • 52 Week Low
  • TECX $13.70
  • BSVN $27.84
  • 52 Week High
  • TECX $61.07
  • BSVN $50.26
  • Technical
  • Relative Strength Index (RSI)
  • TECX 51.42
  • BSVN 55.00
  • Support Level
  • TECX $21.20
  • BSVN $37.62
  • Resistance Level
  • TECX $22.75
  • BSVN $39.41
  • Average True Range (ATR)
  • TECX 1.43
  • BSVN 1.16
  • MACD
  • TECX 0.01
  • BSVN 0.02
  • Stochastic Oscillator
  • TECX 41.32
  • BSVN 60.84

About TECX Tectonic Therapeutic Inc. Common Stock

Tectonic Therapeutic Inc is a biotechnology company focused on the discovery and development of therapeutic proteins and antibodies that modulate the activity of GPCRs. Its technology platform called GEODe, Tectonic is focused on developing biologic medicines that overcome the existing challenges of GPCR-targeted drug discovery to modify the course of disease. Company focus on areas of important unmet medical need, often where therapeutic options are poor or nonexistent, and where new medicines have the potential to improve patient quality of life or extend duration of life. Pipeline includes TX000045, Group 2 PH, TX2100: GPCR Antagonist for Hereditary Hemorrhagic Telangiectasia (HHT), Fibrosis.

About BSVN Bank7 Corp. Common stock

Bank7 Corp is a full-service commercial bank focused on providing customers with exceptional service and meeting their banking needs through a variety of commercial and retail financial services. It offers deposit banking products, including commercial deposit services, commercial checking, money market, and other deposit accounts, and retail deposit services such as certificates of deposit, money market accounts, checking accounts, negotiable order of withdrawal accounts, savings accounts, and automated teller machine access. etc. It generates revenues from interest income from financial instruments and non-interest income and service charges on deposit accounts.

Share on Social Networks: